{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:35:39Z","timestamp":1790937339427,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.coviro.2011.10.024","type":"journal-article","created":{"date-parts":[[2011,11,17]],"date-time":"2011-11-17T16:35:23Z","timestamp":1321547723000},"page":"545-547","source":"Crossref","is-referenced-by-count":23,"title":["Antiviral drugs and antiviral drug resistance"],"prefix":"10.1016","volume":"1","author":[{"given":"Donald M","family":"Coen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J","family":"Whitley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2011.10.024_bib0005","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(82)90658-4","article-title":"Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes","volume":"2","author":"Nilsen","year":"1982","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2011.10.024_bib0010","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJM198406143102402","article-title":"A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection","volume":"310","author":"Douglas","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2011.10.024_bib0015","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1001\/jama.1984.03350090023017","article-title":"Double-blind placebo-controlled trial of oral acycolvir in first-episode genital herpes simplex virus infection","volume":"252","author":"Mertz","year":"1984","journal-title":"JAMA"},{"key":"10.1016\/j.coviro.2011.10.024_bib0020","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1001\/jama.1984.03340400031020","article-title":"Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial","volume":"251","author":"Reichman","year":"1984","journal-title":"JAMA"},{"key":"10.1016\/j.coviro.2011.10.024_bib0025","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJM199709113371102","article-title":"Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy","volume":"337","author":"Gulick","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2011.10.024_bib0030","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJM199709113371101","article-title":"A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200\/\u03bcL or less","volume":"337","author":"Hammer","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2011.10.024_bib0035","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2011.10.024_bib0040","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","article-title":"Response-guided telaprevir combination treatment for hepatitis C virus infection","volume":"365","author":"Sherman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2011.10.024_bib0045","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2011.10.024_bib0050","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprivir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2011.10.024_bib0055","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprivir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2011.10.024_bib0060","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1002\/j.1460-2075.1985.tb04038.x","article-title":"The molecular basis of the specific anti-influenza action of amantadine","volume":"4","author":"Hay","year":"1985","journal-title":"EMBO J"},{"key":"10.1016\/j.coviro.2011.10.024_bib0065","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/0042-6822(91)90075-M","article-title":"Structural characteristics of the M2 protein of influenza A viruses: evidence that it forms a tetrameric channel","volume":"180","author":"Sugrue","year":"1991","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2011.10.024_bib0070","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/0042-6822(92)91239-Q","article-title":"The transmembrane domain of influenza A M2 protein forms amantadine-sensitive proton channels in planar lipid bilayers","volume":"190","author":"Duff","year":"1992","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2011.10.024_bib0075","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/0092-8674(92)90452-I","article-title":"Influenza virus M2 protein has ion channel activity","volume":"69","author":"Pinto","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.coviro.2011.10.024_bib0085","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/358160a0","article-title":"Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir","volume":"358","author":"Littler","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2011.10.024_bib0090","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/358162a0","article-title":"A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells","volume":"358","author":"Sullivan","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2011.10.024_bib0080","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1128\/JVI.71.1.405-411.1997","article-title":"The human cytomegalovirus UL97 protein is a protein kinase that autophosphorylates on serines and threonines","volume":"71","author":"He","year":"1997","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2011.10.024_bib0095","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1128\/AAC.43.8.1941","article-title":"Acyclovir is phosphorylated by the human cytomegalovirus UL97 protein","volume":"43","author":"Talarico","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2011.10.024_bib0100","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1126\/science.1377403","article-title":"Crystal structure at 3.5\u00c5 resolution of HIV-1 reverse transcriptase complexed with an inhibitor","volume":"256","author":"Kohlstaedt","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.coviro.2011.10.024_bib0105","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1128\/AAC.49.11.4721-4732.2005","article-title":"Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity","volume":"49","author":"Dorr","year":"2005","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625711001581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625711001581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T17:32:54Z","timestamp":1593279174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625711001581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S1879625711001581"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2011.10.024","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}